关键词: 脑器质性精神障碍, 利培酮口服液, 奥氮平, 副反应量表

Abstract: AIM: To retrospectively evaluate the efficacy and safety of risperidone oral solution and olanzapine tablets in treating brain organic mental disorders. METHODS: A total of 133 patients, who met diagnostic criteria of CCMD-3 for brain organic mental disorders and were hospitalized in department of psychiatry from May 2007 to May 2011, included 62 patients in risperidone oral solution group and 71 patients in olanzapine tablets group. On the pre-treatment and at the end of the 4th week of treatment, all patients were assessed by Brief Psychiatric Rating Scale(BPRS), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms(SAPS),Treatment Emergent Symptom Scale (TESS) and laboratory tests.RESULTS: There were significant difference in extrapyramidal side effects, prolactin levels, sleepiness and weight gain between pre-treatment and post-treatment(32.3% vs 16.9%,19.4% vs 5.6%,6.5% vs 19.7%,9.7% vs 19.6%, P<0.05) . However, there were no statistically significant difference(P>0.05) in the total scales of BPRS, SANS, SAPS ,TESS and other index of safety.CONCLUSION: The efficacy of risperidone oral solution and olanzapine tablets in treating brain organic mental disorders was equal, especially for mental disorder due to encephalitis the efficacy up to about 80%, but there were some differences in side effects. It was needed to arrange the treating program according to the patients conditions.

Key words: Brain organic mental disorders, Risperidone oral solution, Olanzapine tablets, Treatment emergent symptom scale